RUBY - ルビウス・セラピュ―ティクス (Rubius Therapeutics Inc.) ルビウス・セラピュ―ティクス

 RUBYのチャート


 RUBYの企業情報

symbol RUBY
会社名 Rubius Therapeutics Inc (ルビウス・セラピュ―ティクス)
分野(sector) Health Care   ヘルスケア
産業(industry) Biotechnology: Biological Products (No Diagnostic Substances)  
業種 バイオテクノロジ―_メディカルリサ―チ   医療関連(Health Care)
概要 事業概要 Rubius Therapeutics Inc is a biotechnology company that develops cellular therapies for cancer and enzyme deficiency diseases. The Company develops Red-Cell Therapeutics (RCT) products using red platform. RCT is a red blood cell-based therapy for applications in cancer enzyme replacement therapies and autoimmune disease and tolerance induction. Its RCT product candidate is designed to provide various attributes which include broad therapeutic applications predictable bio-distribution and advantageous tolerability. It is initially focused on advancing RCT product candidates for patients suffering from rare diseases cancer and autoimmune diseases based on three modalities - cellular shielding potent cell-cell interaction and tolerance induction. Its product candidates in rare diseases include RTX-134 for the treatment of phenylketonuria (PKU) RTX-134 followed by RTX-Uricase and RTX-CBS for the treatment of chronic refractory gout symptomatic homocystinuria.   ルビウス・セラピュ―ティクスは米国のバイオ医薬品企業。主に重症患者のための赤血球治療薬の開発に従事する。同社の候補薬はフェニルケトン尿症、ホモシスチン尿症、慢性不応性痛風、急性ポルフィリン症、固形腫瘍、血液がん、自己免疫疾患などの治療に使用される。本社所在地はマサチュ―セッツ州ケンブリッジ。   Rubius Therapeutics is a clinical-stage biopharmaceutical company developing a new class of medicines called Red Cell Therapeutics™. The Company's proprietary RED PLATFORM® was designed to genetically engineer and culture Red Cell Therapeutics™ that are selective, potent and off-the-shelf allogeneic cellular therapies for the potential treatment of several diseases across multiple therapeutic areas.
本社所在地 325 Vassar Street Suite 1A Cambridge MA 02139 USA
代表者氏名 David R. Epstein David R. Epstein
代表者役職名 Chairman of the Board 取締役会会長
電話番号 +1 617-679-9600
設立年月日 41365
市場名 NASDAQ National Market System
ipoyear 2018年
従業員数 83人
url www.rubiustx.com
nasdaq_url https://www.nasdaq.com/symbol/ruby
adr_tso
EBITDA EBITDA(百万ドル) -72.29900
終値(lastsale) 17.01
時価総額(marketcap) 1344514677.03
時価総額 時価総額(百万ドル) 1354
売上高 売上高(百万ドル) 0.00000
企業価値(EV) 企業価値(EV)(百万ドル) 1432.92
当期純利益 当期純利益(百万ドル) -73.79000
決算概要 決算概要 BRIEF: For the six months ended 30 June 2018 Rubius Therapeutics Inc revenues was not reported. Net loss applicable to common stockholders increased from $15.1M to $44.4M. Higher net loss reflects Research and Development - Balancing increase from $7.3M to $19.9M (expense) Stock-based Compensation in SGA increase from $3.5M to $15.5M (expense) General and Administrative - Balancing increase from $1.9M to $6.6M (expense).

 RUBYのテクニカル分析


 RUBYのニュース

   Rubius Therapeutics Inc. (NASDAQ:RUBY) Has Seen A Fall Of -95.81% This Year, Is It Still A Better Option Than Others?  2022/05/20 11:30:00 Marketing Sentinel
In last trading session, Rubius Therapeutics Inc. (NASDAQ:RUBY) saw 1.08 million shares changing hands with its beta currently measuring 2.87. Company’s recent per share price level of $1.08 trading at $0.07 or 6.93% at ring of the bell on the day assigns it a market valuation of $92.97M. That closing price of RUBY’s stock is … Rubius Therapeutics Inc. (NASDAQ:RUBY) Has Seen A Fall Of -95.81% This Year, Is It Still A Better Option Than Others? Read More »
   RUBY stock falls as H.C. Wainwright lowers price target (NASDAQ:RUBY)  2022/05/11 17:56:20 Seeking Alpha
Rubius Therapeutics (RUBY) is trading lower into afternoon trading on Wednesday after H.C
   Rubius Therapeutics GAAP EPS of -$0.58 beats by $0.01  2022/05/10 12:04:27 Seeking Alpha
Rubius Therapeutics press release (RUBY): Q1 GAAP EPS of -$0.58 beats by $0.01.Cash, cash equivalents and investments of $176.5M, will provide a cash runway into the second half of 2023.
   Rubius Therapeutics Reports First Quarter 2022 Financial Results and Provides Business Update  2022/05/10 12:00:00 GlobeNewswire
Presented Updated Clinical Data from Monotherapy Phase 1 Arm of RTX-240 Clinical Trial in Advanced Solid Tumors, Showing Clinical Responses with Favorable Tolerability in PD-(L)1 Refractory Disease
   Earnings Scheduled For May 10, 2022  2022/05/10 09:18:08 Benzinga
Companies Reporting Before The Bell • The Middleby (NASDAQ: MIDD ) is expected to report quarterly earnings at $2.10 per share on revenue of $935.99 million. • Target Hospitality (NASDAQ: TH ) is projected to report earnings for its first quarter. • Hudson Global (NASDAQ: HSON ) is projected to report earnings for its first quarter. • Maiden Hldgs (NASDAQ: MHLD ) is estimated to report earnings for its first quarter. • WhiteHorse Finance (NASDAQ: WHF ) is likely to report earnings for its first quarter. • Anavex Life Sciences (NASDAQ: AVXL ) is estimated to report earnings for its second quarter. • Eos Energy Enterprises (NASDAQ: EOSE ) is estimated to report quarterly loss at $0.56 per share on revenue of $4.32 million. • Navios Maritime Partners (NYSE: NMM ) is estimated to report quarterly earnings at $3.49 per share on revenue of $225.48 million. • Exela Technologies (NASDAQ: XELA ) is expected to report quarterly loss at $0.10 per share on revenue of $284.91 million. • Reata Pharmaceuticals (NASDAQ: RETA ) is likely to report quarterly loss at $2.
   Rubius Therapeutics GAAP EPS of -$0.61 misses by $0.02  2022/02/25 13:08:08 Seeking Alpha
Rubius Therapeutics press release (RUBY): Q4 GAAP EPS of -$0.61 misses by $0.02.As of December 31, 2021, cash and cash equivalents were $225.8M as compared to $176.3M in cash,…
   Rubius Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Business Update  2022/02/25 13:00:00 GlobeNewswire
First Patient Dosed in Phase 1/2 Clinical Trial of RTX-224 in Patients with Certain Advanced Solid Tumors in January 2022 Single-Agent Phase 1 RTX-240 Clinical Trial in Advanced Solid Tumors Continues with No Dose-Limiting Toxicities Observed to Date and an NK Cell Dose Response. Clinical Results Expected in Q1’22
   Rubius Therapeutics to Announce Fourth Quarter and Full Year 2021 Financial Results  2022/02/14 21:15:00 GlobeNewswire
CAMBRIDGE, Mass., Feb. 14, 2022 (GLOBE NEWSWIRE) -- Rubius Therapeutics, Inc. (Nasdaq: RUBY), a clinical-stage biopharmaceutical company that is biologically engineering red blood cells to create an entirely new class of cellular medicines called Red Cell Therapeutics™ for the treatment of cancer and autoimmune diseases, today announced plans to report fourth quarter and full year 2021 financial results on Friday, February 25, 2022, before market open.
   Rubius Therapeutics (RUBY) Investor Presentation IP - Slideshow  2022/02/11 08:36:01 Seeking Alpha
   Rubius Therapeutics begins dosing in phase 1/2 trial of RTX-224 for solid tumors  2022/01/13 14:25:16 Seeking Alpha
Rubius Therapeutics (RUBY) said the first patient was dosed in its phase 1/2 trial of RTX-224 to treat patients with certain relapsed/refractory or locally advanced solid tumors,
   PDT Partners LLC Raises Stock Position in Rubius Therapeutics, Inc. (NASDAQ:RUBY)  2021/11/01 12:58:57 Dakota Financial News
PDT Partners LLC boosted its position in shares of Rubius Therapeutics, Inc. (NASDAQ:RUBY) by 184.7% during the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 45,892 shares of the companys stock after purchasing an additional 29,772 shares during the period. PDT Partners LLC []
   Geode Capital Management LLC Has $19.85 Million Stake in Rubius Therapeutics, Inc. (NASDAQ:RUBY)  2021/11/01 09:16:46 Dakota Financial News
Geode Capital Management LLC boosted its stake in Rubius Therapeutics, Inc. (NASDAQ:RUBY) by 13.2% during the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 813,297 shares of the companys stock after buying an additional 94,744 shares during the quarter. Geode Capital []
   Rubius Therapeutics to Announce Third Quarter 2021 Financial Results  2021/10/28 13:00:00 Intrado Digital Media
CAMBRIDGE, Mass., Oct. 28, 2021 (GLOBE NEWSWIRE) -- Rubius Therapeutics, Inc. (Nasdaq: RUBY), a clinical-stage biopharmaceutical company that is genetically engineering red blood cells to create an entirely new class of cellular medicines called Red Cell Therapeutics for the treatment of cancer and autoimmune diseases, today announced plans to report third quarter financial results on Monday, November 8, 2021, after market close.
   Zacks Investment Research Upgrades Rubius Therapeutics (NASDAQ:RUBY) to Hold  2021/10/26 05:40:42 Transcript Daily
Zacks Investment Research upgraded shares of Rubius Therapeutics (NASDAQ:RUBY) from a sell rating to a hold rating in a research note published on Friday, Zacks.com reports. According to Zacks, Rubius Therapeutics, Inc. is a bio-technology company. It develops cellular therapies for the treatment of auto-immune, metabolic and other diseases. Rubius Therapeutics, Inc. is based in []
   Rubius Therapeutics (NASDAQ:RUBY) Trading Down 4.3%  2021/10/25 19:38:43 Dakota Financial News
Rubius Therapeutics, Inc. (NASDAQ:RUBY) traded down 4.3% on Monday . The company traded as low as $15.40 and last traded at $15.52. 7,932 shares were traded during trading, a decline of 99% from the average session volume of 870,288 shares. The stock had previously closed at $16.22. A number of equities analysts have weighed in []

 関連キーワード  (バイオテクノロジ―_メディカルリサ―チ 米国株 ルビウス・セラピュ―ティクス RUBY Rubius Therapeutics Inc.)

 twitter  (公式ツイッターやCEOツイッターなど)